+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H2 2020

  • ID: 5137296
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 3207 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 4D Pharma Plc
  • Aclaris Therapeutics Inc
  • AiVita Biomedical Inc
  • Aldeyra Therapeutics Inc
  • Amgen Inc
  • AntiCancer Inc
  • MORE
Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Coronavirus Disease - Pipeline Review, H2 2020, provides an overview of the Coronavirus Disease (Infectious Disease) pipeline landscape.

Coronaviruses are a group of viruses belonging to the family Coronaviridae. These viruses cause respiratory infections ranging from the common cold to severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most common symptoms are fever, tiredness, and dry cough. The virus is thought to spread mainly from person-to-person who are in close contact with one another and through respiratory droplets produced when an infected person coughs or sneezes.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Coronavirus Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Coronavirus Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronavirus Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 64, 121, 94, 4, 42, 288, 271 and 11 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 1, 7, 5, 1, 69, 69 and 2 molecules, respectively.

Coronavirus Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coronavirus Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Coronavirus Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coronavirus Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coronavirus Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Coronavirus Disease (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coronavirus Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coronavirus Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4D Pharma Plc
  • Aclaris Therapeutics Inc
  • AiVita Biomedical Inc
  • Aldeyra Therapeutics Inc
  • Amgen Inc
  • AntiCancer Inc
  • MORE
  • Introduction
  • Coronavirus Disease 2019 (COVID-19) - Overview
  • Coronavirus Disease 2019 (COVID-19) - Therapeutics Development
  • Coronavirus Disease 2019 (COVID-19) - Therapeutics Assessment
  • Coronavirus Disease 2019 (COVID-19) - Companies Involved in Therapeutics Development
  • Coronavirus Disease 2019 (COVID-19) - Drug Profiles
  • Coronavirus Disease 2019 (COVID-19) - Dormant Projects
  • Coronavirus Disease 2019 (COVID-19) - Discontinued Products
  • Coronavirus Disease 2019 (COVID-19) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by 4D Pharma Plc, H2 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by A2A Pharmaceuticals Inc, H2 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by AB Science SA, H2 2020
  • Coronavirus Disease 2019 (COVID-19) - Pipeline by AbbVie Inc, H2 2020
List of Figures
  • Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 4D Pharma Plc
  • A2A Pharmaceuticals Inc
  • AB Science SA
  • AbbVie Inc
  • Abivax SA
  • Abnova Corp
  • Aclaris Therapeutics Inc
  • Adaptive Biotechnologies Corp
  • Adjuvance Technologies Inc
  • Aerogen Ltd
  • Afecta Pharmaceuticals Inc
  • Agenus Inc
  • AI Therapeutics
  • AIkido Pharma Inc
  • AIM ImmunoTech Inc
  • AiVita Biomedical Inc
  • Akari Therapeutics Plc
  • Akebia Therapeutics Inc
  • Akers Biosciences Inc
  • Akshaya Bio Inc
  • Akston Biosciences Corp
  • Aldeyra Therapeutics Inc
  • Alexion Pharmaceuticals Inc
  • Alfasigma SpA
  • Algernon Pharmaceuticals Inc
  • AlloVir Inc
  • Alnylam Pharmaceuticals Inc
  • Alphamab Oncology
  • Altimmune Inc
  • Amarin Corp Plc
  • Amgen Inc
  • Ampio Pharmaceuticals Inc
  • AnGes Inc
  • Angion Biomedica Corp
  • Anixa Biosciences Inc
  • Ansun Biopharma Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • Apellis Pharmaceuticals Inc
  • Apeptico Forschung und Entwicklung GmbH
  • Apogenix AG
  • Applied Therapeutics Inc
  • Aptorum Group Ltd
  • Arbutus Biopharma Corp
  • ARCA biopharma Inc
  • Arch Biopartners Inc
  • Arcturus Therapeutics Ltd
  • Argenx SE
  • Aridis Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll